Developments, news and strategies for drug development specific to phase I through Phase III global clinical trial management, execution, project management and outsourcing. Go→
News, articles and issues specific to clinical trial practice and implementation at the investigative site level. Go→
News, developments and strategies related to eClinical, data management, data collection, ePRO, and more information technology used in the drug development chain. Go→
News, articles and issues specific to laboratories role in the clinical trial, including ECG, imaging, genotyping, tissue samples and more. Go→
News, developments and strategies for clinical trials conduct in relation to the FDA, EMEA and other global regulatory authorities overseeing the drug development industry. Go→
News, articles and strategies related to clinical trial design which impact postmarketing studies, therapeutic areas, adaptive trials, statistics, protocols and more. Go→
According to a DIA subgroup analysis of eTMF adoption, 48% of sponsors currently use a combination of paper and electronic trial master file, which is up from a 27% combo rate in 2010.
With this background in mind, I spoke with executives at CRO Worldwide Clinical Trials (WCT) who recently chose TransPerfect’s Trial Interactive platform as its eTMF solution.
Prior to choosing the eTMF, WCT was using a paper-based system, consisting of the usual scanning and storing of documentation, held in file folders. Laurie Myers, head of central records and document management for WCT, noted that when the decision was made to invest into an eTMF, a list of user requirements for their ultimate eTMF choice was developed and ranked and included features such as accessibility, global presence, helpdesk, audit trails, access speeds, among others. Ultimately, the company chose TransPerfect’s Trial Interactive eTMF.
Jim Volpe, director of corporate administrative services for WCT, noted the company is taking a conservative, phased-in approach toward its eTMF implementation, with the first phase goal of increasing the visibility of paper documents globally. “There is still a lot of uncertainty in the industry around eTMF,” he said. Examples included: Do you need wet signatures? What will regulatory authorities allow and not allow in an eTMF? And in the end, Volpe noted, that the CRO is at the mercy of what the sponsors’ auditors are asking for. “As we use it more, and we understand more of what sponsors want, we can move to a more paperless environment,” said Volpe.
In other venues, sponsors and CROs are tackling those same questions. One upcoming event, ClinTech 2013 will feature a track on eTMF. Topics include managing email and the eTMF/TMF; managing TMF quality before an inspection; metrics in TMF; TMF Reference Model Updates and more.
Volpe, Myers and Senior VP of Clinical Operations, Annie Clark, agree the paperless environment is what is desired. However, they are also in agreement that the phased approach will work best with its CRAs, sponsors, and in the future, investigative sites. Clark noted that the ability to offer sponsors operational transparency into quality control for trial is a major driver for the implementation, as well as the sponsors asking CROs for the eTMF capabilities.
Michael Smyth, general manager of TransPerfect’s Life Sciences Division and Trial Interactive, has high hopes for eTMF, and eventually a paperless clinical trial. “Every study still has a level of paper,” Smyth told me. “But more and more sponsors are realizing that the regulators aren’t the bottleneck. It’s their own internal processes. They realize there is technology now for the other things they could be refining in clinical operations.”
For Trial Interactive, the WCT deal follows two others with CROs in the past year: INC Research and Premier Research. Trial Interactive offers other modules, including Study Start-Up, which was another selling point for WCT. “We want to phase this in before we go full on into the startup process. Culture change is always difficult, so we are slowly moving and evaluating what we can do. But study startup is a definite area that is a paper-intensive process,” noted Volpe.
Smyth described the eTMF disconnect for sites: they already have experience with EDC and web-based study portals for document delivery and study management, but then they still have the paper trial binder. He says the sites don’t want the paper, “But sponsors and CROs keep sending it.”
Getting beyond the paper culture, says Smyth can be addressed when the eTMF is determined the agent of record, and the primary resource file. “If that’s stated, then paper just becomes supportive,” said Smyth. Then the next step, and in discussion with a DIA TMF subcommittee is how or when to destruct paper. And he said it is a bigger discussion around the TMF Reference Model and the industry in general, which can involve a pharma’s legal team. “It can be a company decision around keeping paper forever,” said Smyth.
Clark said, “We are quite excited to get to the next step of quality oversight. I think it’s really great, eTMF pulls the project together in a cohesive way. And we are 100% hoping down the line to save some trees.”